152 related articles for article (PubMed ID: 9508337)
1. The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions.
Khare VK; Albino AP; Reed JA
J Cutan Pathol; 1998 Jan; 25(1):2-10. PubMed ID: 9508337
[TBL] [Abstract][Full Text] [Related]
2. Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression.
Reed JA; McNutt NS; Bogdany JK; Albino AP
J Cutan Pathol; 1996 Dec; 23(6):495-505. PubMed ID: 9001979
[TBL] [Abstract][Full Text] [Related]
3. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions.
Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR
Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543
[TBL] [Abstract][Full Text] [Related]
4. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 and D3 expression in melanocytic skin lesions.
Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
7. Atypical melanocytic nevi of the genital type with a discussion of reciprocal parenchymal-stromal interactions in the biology of neoplasia.
Clark WH; Hood AF; Tucker MA; Jampel RM
Hum Pathol; 1998 Jan; 29(1 Suppl 1):S1-24. PubMed ID: 9445124
[TBL] [Abstract][Full Text] [Related]
8. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
9. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
10. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
Piris A; Mihm MC; Hoang MP
Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
[TBL] [Abstract][Full Text] [Related]
11. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
12. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
Skender-Kalnenas TM; English DR; Heenan PJ
J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
[TBL] [Abstract][Full Text] [Related]
13. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
[TBL] [Abstract][Full Text] [Related]
14. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
15. The intermediate filament peripherin is expressed in cutaneous melanocytic lesions.
Prieto VG; McNutt NS; Lugo J; Reed JA
J Cutan Pathol; 1997 Mar; 24(3):145-50. PubMed ID: 9085149
[TBL] [Abstract][Full Text] [Related]
16. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
You Y; Wang SH; Zhang JF; Zheng SY
Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
[TBL] [Abstract][Full Text] [Related]
17. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
18. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions.
Wang H; Shen SS; Wang H; Diwan AH; Zhang W; Fuller GN; Prieto VG
J Cutan Pathol; 2003 Nov; 30(10):599-605. PubMed ID: 14744083
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi.
Konstantina A; Lazaris AC; Ioannidis E; Liossi A; Aroni K
Melanoma Res; 2011 Oct; 21(5):389-94. PubMed ID: 21876459
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of melanoma precursor lesions.
Wang Y; Rao U; Mascari R; Richards TJ; Panson AJ; Edington HD; Shipe-Spotloe JM; Donnelly SS; Kirkwood JM; Becker D
Cell Growth Differ; 1996 Dec; 7(12):1733-40. PubMed ID: 8959342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
